{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-056077","form_type":"8-K","ticker":"BLLN","cik":"0002070849","company_name":"BillionToOne, Inc.","filed_at":"2025-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.526530+00:00","generated_at":"2026-05-16T13:51:51.617418+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BillionToOne Q3 revenue $83.5M (+117% YoY); guides FY2025 revenue $293-299M","bullets":["Q3 total revenue $83.5M (+117% YoY); prenatal revenue $74.1M (+102%), oncology $8.7M (7.6x YoY).","GAAP operating income of $9.6M vs. ($12.6M) loss YoY; net income $1.5M ($0.10 diluted EPS).","Gross margin improved to 70% from 53% YoY; tests delivered up 52% to 165,000; ASP up 44% to $501.","Guides FY2025 revenue $293-299M (93-96% growth); expects positive operating income for Q4 and full year.","Appointed Anthony Pagano (Genmab CFO) as Audit Committee Chair, effective Jan 1, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-056077","json":"https://secwatch.observer/filing/0001628280-25-056077.json","markdown":"https://secwatch.observer/filing/0001628280-25-056077.md","text":"https://secwatch.observer/filing/0001628280-25-056077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070849/000162828025056077/0001628280-25-056077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070849/000162828025056077/blln-20251209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:51:51.617418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}